Astrazeneca Pharma India Share price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 2,442 shares, with a market capitalization of ₹25000000. Its Average Traded Price (ATP) is ₹7037.52, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹7034.50.
Astrazeneca Pharma India has an upper circuit limit of ₹8527.50 and a lower circuit limit of ₹5685.50. The total value traded stands at ₹1.72 CR, and the delivery percentage for the day is 52.81%.
The stock is currently traded with a market lot size of 1. Astrazeneca Pharma India also offers a dividend yield of 0%.
Astrazeneca Pharma India share price chart
Astrazeneca Pharma India Share Key Metrics
Volume
2442.00
Market Cap
17766.25 CR
LTQ@LTP
1@7034.50
ATP
7037.52
Var Margin
14.95 %
Circuit Range
5685.5-8527.5
Delivery %
52.81 %
Value
1.72 CR
ASM/GSM
No
Market Lot
1
Astrazeneca Pharma India Resistance and Support
Pivot 7119.17
Resistance
First Resistance
7157.34
Second Resistance
7208.17
Third Resistance
7246.34
Support
First Support
7068.34
Second Support
7030.17
Third Support
6979.34
Astrazeneca Pharma India Shareholding Pattern
View More- 2016-17
- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Astrazeneca Pharma India Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-10 | Quarterly Results |
| 2026-05-26 | Audited Results & Final Dividend |
| 2026-02-11 | Quarterly Results |
| 2025-11-07 | Quarterly Results |
| 2025-08-14 | Quarterly Results |
| 2025-05-30 | Audited Results & Dividend |
| 2025-02-11 | Quarterly Results |
| 2024-11-13 | Quarterly Results |
| 2024-08-08 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-31 | 2026-07-31 | View More |
Astrazeneca Pharma India News
AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disclosure Of ESG Rating
AstraZeneca Pharma received an ESG rating of 57 from Crisil ESG Ratings. The rating was based on publicly available information, and the company clarified they did not engage Crisil for this assessment.
Aug 24 2026 20:52:14
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
AstraZeneca Pharma India Limited has scheduled a virtual one-on-one interaction with an institutional investor on August 26, 2026. This meeting is part of the company's ongoing engagement with the investment community.
Aug 21 2026 22:24:10
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
AstraZeneca Pharma has scheduled a virtual one-on-one interaction with an institutional investor on August 19, 2026, as part of its ongoing investor relations.
Aug 15 2026 15:41:04
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
AstraZeneca Pharma India reported strong Q1 FY27 results, with revenue up 30% YoY to Rs.682.8 crore and profit after tax of Rs.50.7 crore. The company also announced key regulatory approvals for therapies like Acalabrutinib and Trastuzumab deruxtecan.
Aug 11 2026 00:43:12
AstraZeneca Pharma India Ltd - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
AstraZeneca Pharma India Ltd received permission to import, sell, and distribute its drug Enhertu® for an additional HER2-positive breast cancer indication in India. This approval paves the way for marketing the drug in the country for this specific patient group.
Aug 08 2026 11:34:06
AstraZeneca Pharma India Ltd - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, August 10, 2026
AstraZeneca board will meet on August 10, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Aug 04 2026 10:35:03
Astrazeneca Pharma India Management
| Name | Position |
|---|---|
| Shilpa Divekar Nirula | Chairperson |
| Revathy Ashok | Non Executive Independent Director |
Astrazeneca Pharma India Similar Stocks
Piramal Pharma Ltd.
214.20
-4.48 (2.05%)
Acutaas Chemicals Ltd.
3217.90
-63.70 (1.94%)
Pfizer Ltd.
4694.00
-9.80 (0.21%)
Granules India Ltd.
826.45
-10.20 (1.22%)
Caplin Point Laboratories Ltd.
2552.70
35.50 (1.41%)
Eris Lifesciences Ltd.
1300.70
-14.10 (1.07%)
Shilpa Medicare Ltd.
949.30
45.50 (5.03%)
Onesource Specialty Pharma Ltd.
1517.20
-15.00 (0.98%)
Poly Medicure Ltd.
1780.20
47.20 (2.72%)
Cohance Lifesciences Ltd.
455.50
5.60 (1.24%)
Astrazeneca Pharma India FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in ASTRAZEN
Account Opening Fee
AMC for 1st Year
Auto Square Off Charges
Call & Trade
+ Free 1st Year AMC